UBS Downgrades Array Technologies to Neutral, Lowers Price Target to $5
UBS analyst Jon Windham downgrades Array Technologies (NASDAQ:ARRY) from Buy to Neutral and lowers the price target from $10 to $5.
Stocks · News reference
Xenon Pharmaceuticals, Steel Dynamics, Nucor And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. futures rise, but Xenon plunges 27.6% after pausing psychiatry trial enrollment over neuropsychiatric adverse events; other stocks also fall
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Piper Sandler Initiates Coverage On Array Technologies with Neutral Rating, Announces Price Target of $5
8-K filing — Array Technologies, Inc. (ARRY)
Filed: 2026-08-31 AccNo: 0001628280-26-059584 Size: 172 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Why Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
Alaunos rose 21.8% after adopting amended bylaws; Cheetah Net led gainers, while Xenon dropped 27.6% after pausing study enrollment.
HC Wainwright & Co. Reiterates Neutral on Biohaven, Maintains $10 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Biohaven (NYSE:BHVN) with a Neutral and maintains $10 price target.
FDA Pauses New Enrollment for Biohaven Epilepsy Drug Program
Biohaven reports an FDA partial clinical hold on BHV-7000 new enrollment while keeping pivotal epilepsy trial data readouts on track.